AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SOLSTICE MINERALS LTD

1.945

-0.115-5.58%

Volume:1.30M

Turnover:2.60M

Market Cap:334.70M

PE:-55.19

High:2.070

Open:2.040

Low:1.920

Close:2.060

52wk High:2.500

52wk Low:0.215

Shares:172.08M

Float Shares:142.75M

Volume Ratio:1.79

T/O Rate:0.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.035

EPS(LYR):-0.030

ROE:-19.97%

ROA:-13.92%

PB:17.99

PE(LYR):-64.06

Loading ...

Overview Company News Filings

Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative?

Simply Wall St.

Solstice Minerals Reports Wide Copper-Gold Intercepts at Nanadie Project in Western Australia, Shares Up 4%

MT Newswires Live

Sellas Life Sciences Q2 Loss Narrows

MT Newswires Live

Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, vs. FactSet Est of $0.05 Loss

MT Newswires Live

SELLAS Life Sciences Group (SLS) Stock Trades At A Premium On Book Value Despite A 7x Return

Simply Wall St.

Galinpepimut-S REGAL Readout and Deal Chatter Might Change The Case For Investing In SELLAS (SLS)

Simply Wall St.

SELLAS Life Sciences Group (SLS) Looks Pricey Following Phase 3 REGAL Trial Progress

Simply Wall St.

Sims Fiscal 2026 Outlook Beats Consensus on US Scrap Conditions, Jefferies Says

MT Newswires Live

SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing

Simply Wall St.

Solstice Minerals Says Geological Review at Western Australia Copper-Gold Project Identifies Growth Oppurtunities

MT Newswires Live

Solstice Minerals Intersects Wide Mineralization Beyond Resource Boundary at Western Australia Project; Shares Up 3%

MT Newswires Live

A Look At SELLAS Life Sciences Group (SLS) Valuation After Arbitration And Phase 3 Regal Trial Hopes

Simply Wall St.

Why SELLAS Life Sciences Group (SLS) Is Up 19.7% After Cramer Endorsement And REGAL Trial Focus

Simply Wall St.

Assessing SELLAS Life Sciences Group (SLS) Valuation After Strong Multi-Year Returns And A Sharp One-Day Share Price Drop

Simply Wall St.

SELLAS Life Sciences (SLS) Nears Pivotal AML Data as Cash, Pipeline and ATM Plan Reframe Its Story

Simply Wall St.

High Growth Tech Stocks in US for May 2026

Simply Wall St.

SELLAS Life Sciences Group Q1 Loss Narrows

MT Newswires Live

Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss

MT Newswires Live

Solstice Minerals Extends Nanadie Copper-Gold System in Western Australia; Shares Up 10%

MT Newswires Live

Solstice Minerals Receives Government Co-Funded Drilling Grant for Western Australia Project; Shares Down 4%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/SLS.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLS.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SLS.AU\",,,,,undefined,":{"symbol":"SLS.AU","market":"AU","secType":"STK","nameCN":"SOLSTICE MINERALS LTD","latestPrice":1.945,"timestamp":1787292720000,"preClose":2.06,"halted":0,"volume":1300535,"delay":0,"changeRate":-0.0558252427184466,"nameEN":"SOLSTICE MINERALS LTD","floatShares":142749097,"shares":172083900,"eps":-0.035239,"marketStatus":"Market Closed","change":-0.115,"latestTime":"08-21 16:12:00 AEST","open":2.04,"high":2.07,"low":1.92,"amount":2596444,"amplitude":0.072816,"askPrice":1.945,"askSize":5169,"bidPrice":1.93,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.035239,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"listingDate":1651327200000,"exchange":"ASX","adjPreClose":2.06,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.7915590570228732,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"SLS.AU","preClose":2.06,"auctionPrice":1.945,"auctionVolume":16735,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292599136}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SLS.AU\",,,,,undefined,":{"symbol":"SLS.AU","floatShares":142749097,"roa":"-13.92%","roe":"-19.97%","lyrEps":-0.030362,"volumeRatio":1.7915590570228732,"shares":172083900,"dividePrice":0,"high":2.07,"amplitude":0.072816,"preClose":2.06,"low":1.92,"week52Low":0.215,"pbRate":"17.99","week52High":2.5,"institutionHeld":0,"latestPrice":1.945,"committee":-0.265516,"eps":-0.035239,"divideRate":0,"volume":1300535,"delay":0,"ttmEps":-0.035239,"open":2.04,"prevYearClose":0.41,"prevWeekClose":2.1,"prevMonthClose":2.16,"prevQuarterClose":2.37,"fiveDayClose":2.1,"twentyDayClose":2.36,"sixtyDayClose":1.475},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLS.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLS.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLS.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661521680","title":"Are SELLAS Life Sciences (SLS) Loss Trends Masking a Shifting Cancer Vaccine Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661521680","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661521680?lang=en_us&edition=fundamental","pubTime":"2026-08-22 12:35","pubTimestamp":1787373335,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results, with net loss rising to US$9.61 million from US$6.60 million a year earlier, while basic loss per share from continuing operations narrowed to US$0.05 from US$0.07.\nFor the first half of 2026, the company’s net loss increased to US$18.01 million from US$12.41 million, yet basic loss per share improved to US$0.10 from US$0.13, as investor attention was also drawn to renewed interest in immune-based cancer therapies...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/are-sellas-life-sciences-sls-loss-trends-masking-a-shifting","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/are-sellas-life-sciences-sls-loss-trends-masking-a-shifting","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","SLS","BK4139","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660010474","title":"Solstice Minerals Reports Wide Copper-Gold Intercepts at Nanadie Project in Western Australia, Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660010474","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660010474?lang=en_us&edition=fundamental","pubTime":"2026-08-20 09:23","pubTimestamp":1787189005,"startTime":"0","endTime":"0","summary":"Solstice Minerals  reported wide copper-gold intercepts from two additional diamond tails and further strong results from step-out reverse circulation drilling at its Nanadie copper-gold project in Western Australia, according to a Thursday Australian bourse filing.The results were up to 148 meters at nearly 0.8% copper and 0.2 grams per tonne gold from 201 meters, with the diamond tail component adding 43.4 meters at almost 0.6% copper and 0.15 g/t gold to previously reported mineralization to the end of hole, and 43 meters at nearly 0.6% copper and 0.21 g/t  gold from 175 meters from reverse circulation, the filing added.A steady stream of results is expected over the coming months, it added.The company's shares rose 4% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IAUM","DBC","FGDL","UGL","DULL","GLDM","GLTR","SLS.AU","1OZmain","JNUG","XME","XKO.AU","USG","CPXR","IAU","CPER","CEF","GDXU","DBB","QCmain","BTGD","AAAU","BAR","GDXJ","COPX","XAO.AU","GDXY","GDXD","GBUG","MTX","DUST","WRN","GDX","IAUI","GLL","SGOL","PHYS","DZZ","PICK","COPJ","MHGmain","JDST","ICOP","COPP","XJO.AU","RING","BEGS","SETM","OUNZ","DGP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945979","title":"Sellas Life Sciences Q2 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945979","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945979?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:49","pubTimestamp":1786481380,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences (SLS) reported a Q2 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier.Two analysts polled by FactSet expected a loss of $0.05.As of June 30, the company had cash and cash equivalents of about $138.3 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","SLS.AU","BK4139","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943767","title":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, vs. FactSet Est of $0.05 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943767","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943767?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:31","pubTimestamp":1786480306,"startTime":"0","endTime":"0","summary":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q2 Loss $0.05, vs. FactSet Est of $0.05 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652255493","title":"SELLAS Life Sciences Group (SLS) Stock Trades At A Premium On Book Value Despite A 7x Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2652255493","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652255493?lang=en_us&edition=fundamental","pubTime":"2026-07-19 11:28","pubTimestamp":1784431730,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group stock has delivered a very large three year return while the broader valuation checks suggest the shares are expensive rather than a clear bargain.\n\nOver the past three years, SELLAS Life Sciences Group has returned about 7x, which puts extra attention on whether the current price already reflects much of the good news.\nExpectations for rapid revenue and earnings growth may support the current valuation, while the recently filed US$154.6m shelf registration...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-trades-at-a-premium-on","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-trades-at-a-premium-on","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS","BK4139","BK7104","TSPA","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650922763","title":"Galinpepimut-S REGAL Readout and Deal Chatter Might Change The Case For Investing In SELLAS (SLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650922763","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650922763?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:25","pubTimestamp":1783599920,"startTime":"0","endTime":"0","summary":"In recent comments, SELLAS Life Sciences Group CEO Angelos M. Stergiou addressed concerns about perceived delays in the pivotal Phase 3 REGAL trial for Galinpepimut-S in acute myeloid leukemia, clarifying that there is still no approved maintenance therapy for patients in a second complete remission and that 78 of the 80 required events for final analysis have now occurred.\nAt the same time, a small new position reported by CoreCap Advisors and updated change-of-control terms have fueled...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/galinpepimut-s-regal-readout-and-deal-chatter-might-change-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/galinpepimut-s-regal-readout-and-deal-chatter-might-change-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SLS.AU","BK7104","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646843394","title":"SELLAS Life Sciences Group (SLS) Looks Pricey Following Phase 3 REGAL Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2646843394","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646843394?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:32","pubTimestamp":1782322362,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group (SLS) moved higher after investors focused on fresh updates from its pivotal Phase 3 REGAL trial and on recent shareholder approval to expand the company’s equity incentive plan share pool.\nSee our latest analysis for SELLAS Life Sciences Group.\nThose REGAL updates and the expanded equity plan arrive after a sharp recovery in SELLAS Life Sciences Group, with the stock posting a 71.13% 90 day share price return and a very large 1 year total shareholder return. This...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-looks-pricey-following-phase","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-looks-pricey-following-phase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4097","BK4139","BK7104","SLS","PRGS","LU2065732104.USD","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644790447","title":"Sims Fiscal 2026 Outlook Beats Consensus on US Scrap Conditions, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644790447","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644790447?lang=en_us&edition=fundamental","pubTime":"2026-06-18 11:53","pubTimestamp":1781754820,"startTime":"0","endTime":"0","summary":"Sims (ASX:SGM) is expected to benefit from stronger US scrap recycling market conditions and expanding earnings opportunities in its Sims Lifecycle Services (SLS) business, driving significant upgrade","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS","BK7104","EBIT","BK4139","SGM.AU","SLS.AU","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644422157","title":"SELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644422157","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644422157?lang=en_us&edition=fundamental","pubTime":"2026-06-17 22:31","pubTimestamp":1781706686,"startTime":"0","endTime":"0","summary":"Why the new shelf registration matters for SELLAS Life Sciences Group stock\nSELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common shares, an event that puts potential future capital raising firmly on investors’ radar.\nThe filing follows recent shareholder meetings that backed board proposals and an expanded equity plan. This development sets the stage for possible use of this shelf as SELLAS funds its late stage oncology programs and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-looks-fully-valued-afte","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-stock-looks-fully-valued-afte","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","BK4139","BK7104","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643735133","title":"Solstice Minerals Says Geological Review at Western Australia Copper-Gold Project Identifies Growth Oppurtunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2643735133","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643735133?lang=en_us&edition=fundamental","pubTime":"2026-06-16 12:47","pubTimestamp":1781585227,"startTime":"0","endTime":"0","summary":"Solstice Minerals  said its updated geological review at its Nanadie copper-gold project in Western Australia identified multiple new growth opportunities outside the existing deposit, according to a Tuesday Australian bourse filing.The geological review suggests that both Nanadie and the Stark copper prospect formed as part of the same magmatic copper-gold event. The updated geological model suggests both deposits have a broad accumulation of disseminated copper-gold mineralization in an intrusive setting.The company also began a strategic review process to assess alternatives with regard to the Yarri gold project, the Ponton gold project, and the Ringlock nickel-copper and gold project.Solstice Minerals' shares fell past 2% in recent trading on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JDST","DGP","CEF","GDXD","COPP","GBUG","MHGmain","GDXU","BEGS","BAR","1OZmain","AAAU","CPER","COPJ","GDXY","ICOP","MTX","WRN","DBC","OUNZ","SETM","USG","CPXR","UGL","XJO.AU","XKO.AU","SLS.AU","IAUM","QCmain","COPX","IAUI","RING","XAO.AU","XME","PICK","GLL","GDX","PHYS","DZZ","GDXJ","BTGD","FGDL","GLDM","GLTR","DULL","IAU","JNUG","SGOL","DBB","DUST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642253104","title":"Solstice Minerals Intersects Wide Mineralization Beyond Resource Boundary at Western Australia Project; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642253104","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642253104?lang=en_us&edition=fundamental","pubTime":"2026-06-12 09:17","pubTimestamp":1781227070,"startTime":"0","endTime":"0","summary":"Solstice Minerals (ASX:SLS) intersected wide mineralization zones 160 meters to the north of the current mineral resource estimate boundary at its Nanadie project in Western Australia, according to a ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EIGA.AU","VAP.AU","GIVE.AU","ZYAU.AU","OZF.AU","BK7104","QFN.AU","IIGF.AU","SLS.AU","XME","SLF.AU","OZR.AU","GEAR.AU","XJO.AU","BK4535","IOZ.AU","BK4109","XAO.AU","DACE.AU","E200.AU","XKO.AU","VAS.AU","BEAR.AU","QRE.AU","MTX","WRN","UYM","IISV.AU","BBOZ.AU","STW.AU","BK4168","IMLC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642432284","title":"A Look At SELLAS Life Sciences Group (SLS) Valuation After Arbitration And Phase 3 Regal Trial Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642432284","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642432284?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:12","pubTimestamp":1780949566,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group (SLS) has drawn fresh attention as investors focus on its arbitration with Chinese partner 3D Medicines over GPS, alongside anticipation around Phase 3 Regal trial data and its current cash position.\nSee our latest analysis for SELLAS Life Sciences Group.\nThe latest 1 day share price return of 9% and 7 day return of 9.3% sit against a much stronger 30 day share price return of 64.3% and year to date gain of 89.2%. The 1 year total shareholder return is very large,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/a-look-at-sellas-life-sciences-group-sls-valuation-after-arb","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/a-look-at-sellas-life-sciences-group-sls-valuation-after-arb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SLS","BK7104","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937748","title":"Why SELLAS Life Sciences Group (SLS) Is Up 19.7% After Cramer Endorsement And REGAL Trial Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937748","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640937748?lang=en_us&edition=fundamental","pubTime":"2026-06-01 16:21","pubTimestamp":1780302080,"startTime":"0","endTime":"0","summary":"In late May 2026, CNBC’s Jim Cramer highlighted SELLAS Life Sciences Group on “Mad Money,” calling the biotech a “great spec” and giving it “two thumbs up,” while investors tracked progress in its Phase 3 REGAL trial for GPS in AML patients in remission but ineligible for stem cell transplant.\nAttention is also building around SELLAS’ second AML candidate, SLS009, with upcoming topline data viewed as a potentially important catalyst for the company’s development pipeline.\nWith recent returns...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-up-197-after-cramer-en","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/why-sellas-life-sciences-group-sls-is-up-197-after-cramer-en","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","SLS.AU","SLS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334520","title":"Assessing SELLAS Life Sciences Group (SLS) Valuation After Strong Multi-Year Returns And A Sharp One-Day Share Price Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637334520?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:40","pubTimestamp":1779464437,"startTime":"0","endTime":"0","summary":"Recent Performance Snapshot\nSELLAS Life Sciences Group (SLS) has drawn attention after a sharp 1 day share price decline of 15.7%. This comes alongside far stronger gains over the month, past 3 months, and past year.\nWith the stock closing at US$7.56 and a market value around US$1.67b, recent returns of 50.3% over the month and 82.2% over the past 3 months highlight how volatile sentiment around this cancer focused biopharmaceutical company can be.\nSee our latest analysis for SELLAS Life...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/assessing-sellas-life-sciences-group-sls-valuation-after-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/assessing-sellas-life-sciences-group-sls-valuation-after-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","BK4139","SLS","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636601258","title":"SELLAS Life Sciences (SLS) Nears Pivotal AML Data as Cash, Pipeline and ATM Plan Reframe Its Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2636601258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636601258?lang=en_us&edition=fundamental","pubTime":"2026-05-18 07:24","pubTimestamp":1779060289,"startTime":"0","endTime":"0","summary":"Earlier this week, SELLAS Life Sciences Group reported a first-quarter 2026 net loss of US$8.41 million while confirming its pivotal Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis.\nAlongside this, SELLAS strengthened its cash position to US$107.1 million, advanced its SLS009 candidate into a Phase 2 AML trial, and set up a US$150 million at-the-market equity program, underscoring a balance of late-stage and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-sls-nears-pivotal-aml-data-as-cash-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-sls-nears-pivotal-aml-data-as-cash-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS","BK4139","BK7104","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635711421","title":"High Growth Tech Stocks in US for May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711421","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711421?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:08","pubTimestamp":1778756891,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings expected to grow by 17% annually in the coming years. In this context of robust growth and stability, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation capabilities and adaptability to evolving market demands.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/high-growth-tech-stocks-in-us-for-may-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/high-growth-tech-stocks-in-us-for-may-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","BK4020","RZLT","SLS.AU","SLS","HLIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635983228","title":"SELLAS Life Sciences Group Q1 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2635983228","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635983228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:44","pubTimestamp":1778618688,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group  reported a Q1 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier.Two analysts polled by FactSet expected a loss of $0.06.Cash and cash equivalents were $107.1 million at the end of Q1, compared with $71.8 million at the end of Q4.Shares of the company rose more than 12% in after-hours activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","BK4139","SLS","SLS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240773","title":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240773","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240773?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:31","pubTimestamp":1778617888,"startTime":"0","endTime":"0","summary":"Earnings Flash (SLS) SELLAS Life Sciences Posts Q1 Loss $0.05, vs. FactSet Est of $0.06 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS.AU","SLS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634476735","title":"Solstice Minerals Extends Nanadie Copper-Gold System in Western Australia; Shares Up 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476735","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634476735?lang=en_us&edition=fundamental","pubTime":"2026-05-11 11:48","pubTimestamp":1778471282,"startTime":"0","endTime":"0","summary":"Solstice Minerals  said a follow-up diamond drill hole at its wholly owned Nanadie copper-gold project in Western Australia has been completed to a final depth of 840.4 meters, ending in host geology at the limit of onsite rig capacity, according to a Monday Australian bourse filing.The company said extensive zones of visible chalcopyrite were observed throughout the hole, reinforcing the scale and continuity of the mineralized system, with mineralization intersected to at least 800 meters downhole and sulphide styles and concentrations broadly comparable to those in the previous hole.The drill hole extends the interpreted mineralized system to about 500 meters below the current 2022 mineral resource estimate  boundary, with geological logging and core processing continuing and first laboratory assay results expected in four to six weeks, the filing added.The company is also progressing a concurrent 10,000-meter phase 2 reverse circulation drill program with eight holes completed to da","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLS.AU","BK4168","MRE.AU","XKO.AU","DBB","BK4588","PICK","BK4109","SETM","BK4535","XAO.AU","MTX","XJO.AU","COPX","WRN","BK4585","BK7104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633083976","title":"Solstice Minerals Receives Government Co-Funded Drilling Grant for Western Australia Project; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633083976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633083976?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:59","pubTimestamp":1778029141,"startTime":"0","endTime":"0","summary":"Solstice Minerals (ASX:SLS) received a co-funded drilling grant of up to AU$200,000 under Round 33 of the Western Australian Government's exploration incentive scheme, with an additional allowance of ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4168","XKO.AU","MTX","BK7104","SLS.AU","BK4109","XAO.AU","WRN","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}